mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antidepressant Action of Ketamine: In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959 ; see the Perspective by Cryan and O'Leary ) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have suggested that ketamine can increase the synthesis of synaptic proteins through BDNF signaling dependent on the activate protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) signaling cascades. 378 , 379”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone can also alleviate neural dysfunction linked to symptoms of depression by boosting the synapse and spine density and restoring spinogenesis, in addition to correcting depressive-like behaviors in animal models of depression. 378 , 477”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine rapidly and transiently increases glutamate transmission in the PFC, possibly via inhibition of tonically active GABAergic inter-neurons, and the resulting burst of glutamate is thought to underlie ketamine induction of synapto-genesis (6, 7).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine increases BDNF release and stimulates mTORC1 signaling, which leads to increased levels of synaptic proteins (i.e., GluR1, PSD95, and synapsin 1) and increased number and function of synapses in the PFC 4,22,35 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Functional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Self-citation
Cited by
Items 201–300 of 1,062
Antidepressant Effects of the Muscarinic Cholinergic Receptor Antagonist Scopolamine: A Review
Drevets, W. C., Zarate, C. A., & Furey, M. L. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.031 · Cited by 195
“(68) reported that ketamine administration rapidly activates the mammalian target of rapamycin (mTOR) pathway, leading to increased synaptic signaling protein expression and increased number and function of new spine synapses in the rodent prefrontal cortex.”
mTOR signaling in stem and progenitor cells
Meng, D., Frank, A. R., & Jewell, J. L. (2018) · Development · doi:10.1242/dev.152595 · Cited by 193
“In line with this, ketamine, a glutamate N-methyl-Daspartic acid (NMDA) receptor antagonist that activates mTORC1 via MAPK-AKT signaling (Li et al., 2010), improves hippocampal neuron formation in aged mice (Romine et al., 2015) (Fig.”
BackgroundYang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Psychiatric Disorders: Diagnosis to Therapy
Krystal, J. H., & State, M. W. (2014) · Cell · doi:10.1016/j.cell.2014.02.042 · Cited by 190
Naughton, M., Clarke, G., O′Leary, O. F., Cryan, J. F., & Dinan, T. G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.014 · Cited by 190
“These signalling events activate mTOR (mammalian target of rapamycin), leading to increased synaptic proteins and spine densities (in preclinical studies of rat prefrontal cortices) resulting in synaptogenesis (Li et al., 2010).”
BackgroundInfluentialOlloquequi, J., Cornejo-Córdova, E., Verdaguer, E., Soriano, F. X., Binvignat, O., Auladell, C., & Camins, A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754680 · Cited by 189
Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814709116 · Cited by 188
“These effects of (2R,6R)-HNK occur in the absence of NMDA receptor blockade (9) but converge with the downstream actions of ketamine, which produces activity-dependent effects on BDNF release via blockade of NMDA receptors on GABA interneurons and disinhibition of glutamate transmission (11, 52, 53).”
BackgroundMethodSelf-citationCholinergic regulation of mood: from basic and clinical studies to emerging therapeutics
Dulawa, S. C., & Janowsky, D. S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0219-x · Cited by 187
“Yet over the last decade, a far greater number of basic and clinical studies have investigated the therapeutic effects and mechanism of action of the NMDA antagonist, ketamine, compared to scopolamine 124–126 .”
BackgroundNeurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine
Deyama, S., & Duman, R. S. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172837 · Cited by 186
Self-citationPham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
“Complementary electrophysiological data have been obtained measuring excitatory postsynaptic current either in cortical or hippocampal slices (Li et al., 2010).”
BackgroundMethodResultInfluentialThe role of mTOR in depression and antidepressant responses
Abelaira, H. M., Réus, G. Z., Neotti, M. V., & Quevedo, J. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.02.014 · Cited by 186
“Thus, further characterization of these actions of NMDA receptor blockade and signaling pathways that stimulate mTOR signaling andmediate the rapid induction of synapses in the hippocampus, amygdala, prefrontal cortex and striatum will provide novel therapeutic targets for antidepressant drug development (Li et al., 2…”
BackgroundInfluentialThe role of brain derived neurotrophic factor in central nervous system
Li, Y., Li, F., Qin, D., Chen, H., Wang, J., Wang, J., Song, S., Wang, C., Wang, Y., Liu, S., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.986443 · Cited by 186
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
Abdallah, C. G., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., Sherif, M., Ahn, K.-H., D’Souza, D. C., Formica, R., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0644-9 · Cited by 184
“First, this study failed to validate the prediction from preclinical studies [10, 16], in that rapamycin pretreatment did not reduce the acute antidepressant effects of ketamine at 24 h following treatment.”
BackgroundMethodResultSelf-citationZhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., & Hashimoto, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4062-3 · Cited by 183
“Accumulating evidence indicates that AMPA receptors are crucial for the antidepressant effects of ketamine because these effects are blocked by the AMPA receptor antagonist, NBQX (Li et al. 2010, 2011; Maeng et al. 2008; Koike et al. 2011; Koike and Chaki 2014; Freudenberg et al. 2015).”
BackgroundAdvancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap
Pratt, J., Winchester, C., Dawson, N., & Morris, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3649 · Cited by 183
“Df(16)A , Lgdel and Df1 mice are mutant mice with deletions of mouse chromosome 16, which models a microdeletion on human chromosome 22q11.”
BackgroundGuardiola‐Lemaitre, B., De Bodinat, C., Delagrange, P., Millan, M. J., Munoz, C., & Mocaër, E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12720 · Cited by 182
“, 2009), similarly increased PSD-95 and synapsin I expressions, resulting in synaptic strengthening (Li et al., 2010; Li and Jope, 2010).”
BackgroundDepression as a Glial-Based Synaptic Dysfunction
Rial, D., Lemos, C., Pinheiro, H., Duarte, J. M., Gonçalves, F. Q., Real, J. I., Prediger, R. D., Gonçalves, N., Gomes, C. A., Canas, P. M., et al. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00521 · Cited by 182
Pharmacological treatment of PTSD – Established and new approaches
Steckler, T., & Risbrough, V. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.012 · Cited by 182
Identifying fast-onset antidepressants using rodent models
Ramaker, M. J., & Dulawa, S. C. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.36 · Cited by 182
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
“While this discrepancy might suggest that PPI deficits in schizophrenics are not due to NMDA receptor hypofunction, recent research indicates that acute ketamine challenge results in a rebound increase in glutamatergic neurotransmission (Li et al. 2010).”
A Critical Role for GluN2B-Containing NMDA Receptors in Cortical Development and Function
Wang, C.-C., Held, R. G., Chang, S.-C., Yang, L., Delpire, E., Ghosh, A., & Hall, B. J. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.023 · Cited by 180
Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder
Bunney, B. G., Li, J. Z., Walsh, D. M., Stein, R., Vawter, M. P., Cartagena, P., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Watson, S. J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.138 · Cited by 180
Metabolism and metabolomics of ketamine: a toxicological approach
Dinis-Oliveira, R. J. (2017) · Forensic Sciences Research · doi:10.1080/20961790.2017.1285219 · Cited by 178
Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism
Gigliucci, V., O’Dowd, G., Casey, S., Egan, D., Gibney, S., & Harkin, A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3024-x · Cited by 177
“Previous investigations have shown antidepressant-like activity at doses of 10 and 15 mg/kg following acute administration of ketamine in the rat FST (Garcia et al. 2008b; Li et al. 2010).”
InfluentialGassen, N. C., Hartmann, J., Zschocke, J., Stepan, J., Hafner, K., Zellner, A., Kirmeier, T., Kollmannsberger, L., Wagner, K. V., Dedic, N., et al. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001755 · Cited by 177
“The dissociative anesthetic ketamine and the tropane alkaloid scopolamine have been proposed as fast-acting antidepressants [57,58].”
BackgroundRole of Tet1 and 5-hydroxymethylcytosine in cocaine action
Feng, J., Shao, N., Szulwach, K. E., Vialou, V., Huynh, J., Zhong, C., Le, T., Ferguson, D., Cahill, M. E., Li, Y., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3976 · Cited by 177
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder
Niciu, M. J., Ionescu, D. F., Richards, E. M., & Zarate, C. A. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1130-x · Cited by 155
“…by the translational inhibitor anisomycin, but not by the RNA polymerase/transcriptional inhibitor actinomycin D. Consistent with prior studies (Li et al. 2010, 2011), the antidepressant effects of ketamine could be prevented by pretreatment with NBQX, a…”
InfluentialFeter, N., Caputo, E. L., Doring, I. R., Leite, J. S., Cassuriaga, J., Reichert, F. F., da Silva, M. C., Coombes, J. S., & Rombaldi, A. J. (2020) · Public Health · doi:10.1016/j.puhe.2020.11.013 · Cited by 178
Bagot, R. C., Cates, H. M., Purushothaman, I., Vialou, V., Heller, E. A., Yieh, L., LaBonté, B., Peña, C. J., Shen, L., Wittenberg, G. M., et al. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.06.012 · Cited by 176
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175
“…dendritic spines density, dendritic length and branches, neurotrophic factors (BNDF) and synaptic proteins such as synapsin, synaptophysin, post-synaptic density protein 95 (PSD95) and metabotropic glutamate receptors (mGluR), in the hippocampus and PFC (Li et al., 2010; Duman et al., 2016).”
BackgroundNew targets for rapid antidepressant action
Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 154
Lepack, A. E., Bang, E., Lee, B., Dwyer, J. M., & Duman, R. S. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.011 · Cited by 174
“A recent report demonstrates that GLYX-13 also causes a rapid increase in the number of spine synapses in the PFC (Burgdorf et al., 2015a).”
InfluentialSelf-citationKetamine and other glutamate receptor modulators for depression in adults
Caddy, C., Amit, B. H., McCloud, T. L., Rendell, J. M., Furukawa, T. A., McShane, R., Hawton, K., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub2 · Cited by 174
Fukumoto, K., Iijima, M., & Chaki, S. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.233 · Cited by 174
De Berardis, D., Fornaro, M., Valchera, A., Cavuto, M., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102888 · Cited by 174
“mTOR, indeed, represents an essential target of ketamine in the prefrontal cortex of animal models of depressive states, and the activation of mTOR by ketamine also provokes the increase in mRNA and protein levels of activity-regulated cytoskeletal-associated protein Arc, synapsin I, postsynaptic density protein 95 (P…”
BackgroundKoike, H., & Chaki, S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.065 · Cited by 175
NMDA Receptor Activity in Neuropsychiatric Disorders
Lakhan, S. E., Caro, M., & Hadzimichalis, N. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00052 · Cited by 151
“…Hospital of Basel, Switzerland Reviewed by: Paul C. Fletcher, University of Cambridge, UK Bernat Kocsis, Harvard Medical School, USA Henry H. Holcomb, University of Maryland School of Medicine, USA *Correspondence: Shaheen E. Lakhan, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue,…”
BackgroundWilkinson, S. T., & Sanacora, G. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.007 · Cited by 173
“Preclinical evidence suggests that ketamine causes a dose-dependent surge in glutamate release at the tripartite synapse, which leads to enhanced signaling through AMPARs, downstream upregulation of synaptic proteins, and increased BDNF activity [34].”
BackgroundYang, C., Hu, Y.-M., Zhou, Z.-Q., Zhang, G.-F., & Yang, J.-J. (2013) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.724118 · Cited by 173
“(7) have reported that an mTOR-induced rapid formation of synapses is an underlying mechanism for ketamine in exerting its rapid antidepressant effect.”
BackgroundKetamine as a Novel Antidepressant: From Synapse to Behavior
Murrough, J. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.244 · Cited by 172
Disruption of alcohol-related memories by mTORC1 inhibition prevents relapse
Barak, S., Liu, F., Hamida, S. B., Yowell, Q. V., Neasta, J., Kharazia, V., Janak, P. H., & Ron, D. (2013) · Nature Neuroscience · doi:10.1038/nn.3439 · Cited by 172
“For example, the translation of the synaptic proteins, Arc 28 , PSD-95 29, 30 , and the AMPA and NMDA receptor subunits, GluR1 30, 31 and NR1 31 , respectively, is mTOR1 dependent.”
Musazzi, L., Treccani, G., Mallei, A., & Popoli, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.009 · Cited by 172
Ignácio, Z. M., Réus, G. Z., Arent, C. O., Abelaira, H. M., Pitcher, M. R., & Quevedo, J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12845 · Cited by 172
Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
“In particular, a single administration of the GluN2B-acting NMDAR antagonist Ro 25-6981 decreases behavioral despair in the 24-h forcedswim test [42, 47, 93, 94], novelty-suppressed feeding test [42, 47, 55], and novelty-induced hypophagia [56] and”
BackgroundInfluentialSelf-citationWang, J., Goffer, Y., Xu, D., Tukey, D. S., Shamir, D. B., Eberle, S. E., Zou, A. H., Blanck, T. J. J., & Ziff, E. B. (2011) · Anesthesiology · doi:10.1097/aln.0b013e31822f16ae · Cited by 171
“5 days) of ketamine therapy in our model was highly compatible with other models of depression.(32,38,61) This suggests that the underlying mechanism of ketamine’s antidepressant”
ResultWang, S., Ishima, T., Zhang, J., Qu, Y., Chang, L., Pu, Y., Fujita, Y., Tan, Y., Wang, X., & Hashimoto, K. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01916-z · Cited by 171
Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
Cameron, L. P., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00101 · Cited by 115
Role of calcium, glutamate and NMDA in major depression and therapeutic application
Deutschenbaur, L., Beck, J., Kiyhankhadiv, A., Mühlhauser, M., Borgwardt, S., Walter, M., Hasler, G., Sollberger, D., & Lang, U. E. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.02.015 · Cited by 171
mTOR activation is required for the antidepressant effects of mGluR2/3 blockade
Dwyer, J. M., Lepack, A. E., & Duman, R. S. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001702 · Cited by 169
“Previously, our lab has demonstrated that the NMDA receptor antagonist ketamine rapidly increases mTOR signaling (Li et al., 2010), and here, we demonstrate similar findings in response to mGluR2/3 blockade.”
BackgroundMethodResultInfluentialSelf-citationAntidepressant Effects of Fibroblast Growth Factor-2 in Behavioral and Cellular Models of Depression
Elsayed, M., Banasr, M., Duric, V., Fournier, N. M., Licznerski, P., & Duman, R. S. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.003 · Cited by 169
“It is important to consider potential confounding effects of ketamine given reports that this agent produces antidepressant actions in rodent models (25, 26).”
BackgroundSelf-citationNiculescu, A. B., Levey, D. F., Phalen, P. L., Le-Niculescu, H., Dainton, H. D., Jain, N., Belanger, E., James, A., George, S., Weber, H., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.112 · Cited by 169
A historical review of antidepressant effects of ketamine and its enantiomers
Wei, Y., Chang, L., & Hashimoto, K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172870 · Cited by 157
Translating Glutamate: From Pathophysiology to Treatment
Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002804 · Cited by 168
“In a series of elegant studies by the Duman lab, it was reported that ketamine rapidly activates mTOR pathway, leading to increased synaptic signaling proteins and increased number and function of new spine synapses in the prefrontal cortex of rats (147).”
BackgroundCarlson, P. J., Diazgranados, N., Nugent, A. C., Ibrahim, L., Luckenbaugh, D. A., Brutsche, N., Herscovitch, P., Manji, H. K., Zarate, C. A., & Drevets, W. C. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.008 · Cited by 168
Enhanced Neuronal Activity in the Medial Prefrontal Cortex during Social Approach Behavior
Lee, E., Rhim, I., Lee, J. W., Ghim, J.-W., Lee, S., Kim, E., & Jung, M. W. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0307-16.2016 · Cited by 168
“Social stress causes reduced mPFC neural activity and social avoidance, effects that can be reversed by ketamine treatment, optogenetic stimulation of mPFC neurons, or optogenetic modulation of dopaminergic projections to the mPFC (Covington et al., 2010; Li et al., 2010; Chaudhury et al., 2013; Lee et al., 2015).”
BackgroundWaters, E. M., Thompson, L. I., Patel, P., Gonzales, A. D., Ye, H. (., Filardo, E. J., Clegg, D. J., Gorecka, J., Akama, K. T., McEwen, B. S., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1298-14.2015 · Cited by 149
“25 mM NaF, 1 mM NaVO3) with freshly added protease inhibitor cocktail (Sigma-Aldrich; Li et al., 2010).”
MethodInfluentialIrwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167
Tolahunase, M. R., Sagar, R., Faiq, M., & Dada, R. (2018) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-170810 · Cited by 167
“Elevated mTOR signaling promotes the synthesis of synaptic proteins that are necessary for synapse formation and maturation (Abelaira et al., 2014; N. Li et al., 2010).”
Bedrosian, T. A., Fonken, L. K., Walton, J. C., Haim, A., & Nelson, R. J. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.01.004 · Cited by 167
“Indeed, some studies regarding rodent chronic stress models have shown anhedonia to coexist with heightened novelty-seeking behavior (Shumake et al., 2005; Li et al., 2010a,b); however, further behavioral testing is necessary to either support or refute these relations in our model.”
Peripheral administration of lactate produces antidepressant-like effects
Carrard, A., Elsayed, M., Margineanu, M., Boury-Jamot, B., Fragnière, L., Meylan, E. M., Petit, J.-M., Fiumelli, H., Magistretti, P. J., & Martin, J.-L. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.179 · Cited by 167
Corticosteroid-Induced Neural Remodeling Predicts Behavioral Vulnerability and Resilience
Gourley, S. L., Swanson, A. M., & Koleske, A. J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2138-12.2013 · Cited by 155
“…agents that target actin cytoskeletal regulators directly, or those that act indirectly—for example, ketamine, an NMDA receptor antagonist, has rapid antidepressant-like properties that are in part attributed to dendritic spine proliferation in deep-layer prefrontal cortex (Li et al., 2010).”
BackgroundKohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 142
“Ketamine acutely induces the phosphorylation of mTOR, p70-S6K, eukaryotic translation initiation factor 4E-binding protein 1, p44/42-MAPK, and Akt, which are believed to influence the subsequently upregulated expression of synaptic proteins such as Arc, synapsin I, postsynaptic density protein 95 (PSD95), and GluR1 [1…”
BackgroundInfluentialPsychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165
Toward Circuit Mechanisms of Pathophysiology in Depression
Spellman, T., & Liston, C. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20030280 · Cited by 165
mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis
Citraro, R., Leo, A., Constanti, A., Russo, E., & De Sarro, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.039 · Cited by 164
Next-Generation Treatments for Mental Disorders
Insel, T. R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004873 · Cited by 164
A non-hallucinogenic LSD analog with therapeutic potential for mood disorders
Lewis, V., Bonniwell, E. M., Lanham, J. K., Ghaffari, A., Sheshbaradaran, H., Cao, A. B., Calkins, M. M., Bautista-Carro, M. A., Arsenault, E., Telfer, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112203 · Cited by 167
“We focused on the prefrontal cortex (PFC), given its central role in the response to rapidly acting antidepressants 67–70 and controlling active stress-coping behaviors.”
BackgroundKetamine for the treatment of addiction: evidence and potential mechanisms
Ivan Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.017 · Cited by 163
“Despite the small sample size and the limited follow-up, this result and anti-depressant effects observed in animal models of depression (Moghaddam et al., 1997; Li et al., 2010; Autry et al., 2011) encouraged researchers in the field to perform more studies in humans (Krystal et al. 2013).”
InfluentialTreatment-resistant depression: are animal models of depression fit for purpose?
Willner, P., & Belzung, C. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4034-7 · Cited by 164
“In the CMS model, a single injection of ketamine reversed not only the anhedonic and other behavioural deficits, but also the atrophy of dendritic spines in the PFC and the associated electrophysiological deficits (Li et al. 2010, 2011b; Duman et al. 2012).”
BackgroundTo use or not to use: an update on licit and illicit ketamine use
Li, J.-H., Kasinather, V., Cheung, Zhou, Nurhidayat, Jarlais, D., & Schottenfeld, R. (2011) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s15458 · Cited by 147
“In contrast, a recent investigation revealed that ketamine treatment can activate the mammalian target of rapamycin (mTOR) pathway to strengthen synapses in the prefrontal cortex of rats.(45) In rat depression models, blockade of mTOR N M D A GLY GLY”
Stress and VTA synapses: implications for addiction and depression
Polter, A. M., & Kauer, J. A. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12490 · Cited by 143
“ketamine has a rapid antidepressant effect has increased interest in synaptic mechanisms of antidepressant action (Zarate et al., 2006; Li et al., 2010; Autry et al., 2011; Mathews & Zarate, 2013).”
BackgroundExercise training improves motor skill learning via selective activation of mTOR
Chen, K., Zheng, Y., Wei, J.-A., Ouyang, H., Huang, X., Zhang, F., Lai, C. S. W., Ren, C., So, K.-F., & Zhang, L. (2019) · Science Advances · doi:10.1126/sciadv.aaw1888 · Cited by 162
Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function
Duman, R. S., Shinohara, R., Fogaça, M. V., & Hare, B. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0400-x · Cited by 154
“increase in levels of synaptic proteins, including GluA1, PSD95, and synapsin 1 in the mPFC [36, 41].”
BackgroundMethodInfluentialSelf-citationBiochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 129
Neural mechanism underlying depressive-like state associated with social status loss
Fan, Z., Chang, J., Liang, Y., Zhu, H. L., Zhang, C., Zheng, D., Wang, J., Xu, Y., Li, Q.-J., & Hu, H. (2023) · Cell · doi:10.1016/j.cell.2022.12.033 · Cited by 164
Donahue, R. J., Muschamp, J. W., Russo, S. J., Nestler, E. J., & Carlezon, W. A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.014 · Cited by 161
“Ketamine also has rapid antidepressant-like effects in other animal models, including the forced swim test and tail suspension test (40–44,48,50), learned helplessness paradigm (45,50,51), and chronic mild stress paradigm (46,47,49).”
BackgroundPehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161
“In support of a role for AMPA receptors in treating depression, preclinical studies suggest that ketamine exerts its antidepressant-like effect through AMPA receptors,(39) and that fast action is accompanied by rapid neuronal and synaptic adaptation.(32,40) It is widely believed that neuroadaptive changes represent a…”
Ma, H., Li, C., Wang, J., Zhang, X., Li, M., Zhang, R., Huang, Z., & Zhang, Y. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019409118 · Cited by 161
“Purified synaptosomes were extracted according to a previous study (64).”
MethodNiciu, M. J., Henter, I. D., Luckenbaugh, D. A., Zarate, C. A., & Charney, D. S. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135950 · Cited by 161
“It also had antidepressant-like effects in the same behavioral models of depression, and these effects were reversed by rapamycin pretreatment (55).”
BackgroundMethodResultInfluentialAkinfiresoye, L., & Tizabi, Y. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3153-2 · Cited by 149
“, synapsin) or the signal transduction mediated via mTOR can occur rather quickly, which may contribute to the acute effectiveness of antidepressants such as ketamine (Li et al. 2010; Duman et al. 2012).”
InfluentialNeuronal correlates of depression
Chaudhury, D., Liu, H., & Han, M.-H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2044-6 · Cited by 144
“Furthermore, increased net glutamatergic surge leads to increased postsynaptic AMPA receptor activation of neuroplasticity-related signalling pathways involving BDNF and mTOR, resulting in overall synaptogenesis and synaptic potentiation [48, 59, 68, 69].”
BackgroundNMDA receptors and metaplasticity: Mechanisms and possible roles in neuropsychiatric disorders
Zorumski, C. F., & Izumi, Y. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.011 · Cited by 139
Sanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
“…selective NMDAR antagonist MK-801 (Autry et al, 2011; Lima-Ojeda et al, 2013; Maeng et al, 2008), and the NR2B selective antagonist RO-25-6981 (Li et al, 2010; Lima-Ojeda et al, 2013; Maeng et al, 2008), have repeatedly and fairly consistently been shown to have antidepressant-like properties…”
BackgroundMajor Depression: One Brain, One Disease, One Set of Intertwined Processes
Filatova, E. V., Shadrina, M. I., & Slominsky, P. A. (2021) · Cells · doi:10.3390/cells10061283 · Cited by 160
Clinically Significant Drug Interactions with Newer Antidepressants
Spina, E., Trifirò, G., & Caraci, F. (2012) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 160
Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders
Roberts-Wolfe, D., & Kalivas, P. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150529144655 · Cited by 145
“Also along these lines, subanesthetic ketamine administration signals via mammalian target of rapamycin (mTOR) activation (93) and mTOR activation is necessary for the epidermal growth factor (EGF) and insulin mediated upregulation of GLT-1 in cultured astrocytes (94).”
BackgroundKocsis, B. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.10.002 · Cited by 159
Nowak, W., Grendas, L. N., Sanmarco, L. M., Estecho, I. G., Arena, Á. R., Eberhardt, N., Rodante, D. E., Aoki, M. P., Daray, F. M., Carrera Silva, E. A., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.063 · Cited by 159
“It has been described that in the CNS, ketamine activates NMDAR and mTOR pathway, inducing an increase of protein synthesis and synaptic strength [33], but how ketamine programs monocyte and macrophages to become an anti-inflammatory responder was not clearly explored.”
BackgroundMethodInfluentialLegal highs: staying on top of the flood of novel psychoactive substances
Baumeister, D., Tojo, L. M., & Tracy, D. K. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314559539 · Cited by 159
“2010] through activation of intracellular secondary messenger systems affecting processes such as synaptogenesis [Li et al. 2010].”
BackgroundMolecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine
Wohleb, E. S., Gerhard, D., Thomas, A., & Duman, R. S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160309114549 · Cited by 148
Self-citationLumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816071116 · Cited by 158
“In addition, the possibility cannot be ruled out that immediate changes in mBDNF and mTOR activation occur in a narrow time window following a treatment (34, 35) and may, therefore, have been missed in the earlier study.”
BackgroundResultKim, C. S., Chang, P. Y., & Johnston, D. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.027 · Cited by 158
“Recently, it has been reported that a low dose of ketamine increasedBDNFprotein synthesis and activatedmTOR signaling pathway, leading to antidepressant-like effect (Autry et al., 2011; Li et al., 2010).”
InfluentialOverview of Glutamatergic Dysregulation in Central Pathologies
Miladinovic, T., Nashed, M., & Singh, G. (2015) · Biomolecules · doi:10.3390/biom5043112 · Cited by 137
“In rats, administration of ketamine caused rapid activation of the mammalian target of rapamycin (mTOR) pathway, which is involved in synaptogenesis, and blocking mTOR signalling effectively blocked ketamine-induced synaptogenesis [56].”
BackgroundRemodeling of axo-spinous synapses in the pathophysiology and treatment of depression
Licznerski, P., & Duman, R. S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.057 · Cited by 157
“Ketamine rapidly activates mTOR signaling in rat PFC, including increased levels of the phosphorylated and activated forms of mTOR, p70S6 kinase, and 4EBP1 (Li et al., 2010).”
InfluentialSelf-citationGuanosine and its role in neuropathologies
Bettio, L. E. B., Gil‐Mohapel, J., & Rodrigues, A. L. S. (2016) · Purinergic Signalling · doi:10.1007/s11302-016-9509-4 · Cited by 158
MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c
Gururajan, A., Naughton, M. E., Scott, K. A., O'Connor, R. M., Moloney, G., Clarke, G., Dowling, J., Walsh, A., Ismail, F., Shorten, G., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.131 · Cited by 144
Metadata
- Authors
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S.
- Affiliations
- Yale University (US)
- Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA.
- Corresponding author
- Duman, Ronald S.
- Venue
- Science
- Published
- 2010-08-20
- Volume
- 329
- Issue
- 5994
- Pages
- 959-964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3116441
- OpenAlex
- W2089351762
- Cited by
- 2,881
- References
- 14
- Citations by year
- 2026: 147 · 2025: 161 · 2024: 171 · 2023: 175 · 2022: 218 · 2021: 234 · 2020: 233 · 2019: 202 · 2018: 199 · 2017: 171 · 2016: 205 · 2015: 217 · 2014: 136 · 2013: 153 · 2012: 125
- FWCI
- 96.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute of Mental Health (2P01 MH25642, MH-45481, P01MH025642, R01MH045481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, mTOR signaling, synaptogenesis, NMDA receptor antagonists, rapid antidepressant effects, treatment-resistant depression, prefrontal cortex, dendritic spines, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Neurons, Neuropeptides, Phenols, Piperidines, Synapses, Time Factors, Protein Biosynthesis, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Sirolimus, Intracellular Signaling Peptides and Proteins, Dendritic Spines, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.